Teva Pharmaceutical Industries (NYSE:TEVA) recently witnessed a 14% rise in stock prices due to the FDA acceptance of their new drug application. But surprisingly, their stock also saw a consequential decrease of 14%, with the CEO attributiΔ±ng it to their own increased success. Recent reports seem to indicate that Teva currently stands as one of the most undervalued healthcare stocks according to certain analysts. This belief appears to be shared by the National Bank of Canada FI, which lifted its position in Teva stock. Notable investments have been made by companies including Arrowstreet Capital Limited Partnership, Sei Investments Co., and Pictet Asset Management Holding SA. Also noteworthy are the views of several analysts and commentators such as Jim Cramer and investment firms such as Bourgeon Capital citing Teva as a top stock pick. Teva garnered attention by providing Q1 2025 earnings guidance and has an upcoming financial guide revealing key performance metrics and outlook data. After scoring a win with a Sanofi-tied drug, Teva catapulted 26%, hitting a six-year high. However, Teva's 2025 guidance seems to have startled investors, creating an opportunity in the dip.
